KR20220052919A - Tgf 베타 결합 도메인을 포함하는 키메라 사이토카인 수용체 - Google Patents

Tgf 베타 결합 도메인을 포함하는 키메라 사이토카인 수용체 Download PDF

Info

Publication number
KR20220052919A
KR20220052919A KR1020227004538A KR20227004538A KR20220052919A KR 20220052919 A KR20220052919 A KR 20220052919A KR 1020227004538 A KR1020227004538 A KR 1020227004538A KR 20227004538 A KR20227004538 A KR 20227004538A KR 20220052919 A KR20220052919 A KR 20220052919A
Authority
KR
South Korea
Prior art keywords
leu
ser
pro
glu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227004538A
Other languages
English (en)
Korean (ko)
Inventor
레지나 준후이 린
블라콤 토마스 존 반
실러 파노스키
샨샨 랑
바브라 존슨 사수
Original Assignee
알로젠 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알로젠 테라퓨틱스 인코포레이티드 filed Critical 알로젠 테라퓨틱스 인코포레이티드
Publication of KR20220052919A publication Critical patent/KR20220052919A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227004538A 2019-08-30 2020-08-28 Tgf 베타 결합 도메인을 포함하는 키메라 사이토카인 수용체 Pending KR20220052919A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962894658P 2019-08-30 2019-08-30
US62/894,658 2019-08-30
US202063053322P 2020-07-17 2020-07-17
US63/053,322 2020-07-17
PCT/US2020/048402 WO2021041806A1 (en) 2019-08-30 2020-08-28 Chimeric cytokine receptors comprising tgf beta binding domains

Publications (1)

Publication Number Publication Date
KR20220052919A true KR20220052919A (ko) 2022-04-28

Family

ID=72521701

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227004538A Pending KR20220052919A (ko) 2019-08-30 2020-08-28 Tgf 베타 결합 도메인을 포함하는 키메라 사이토카인 수용체

Country Status (11)

Country Link
US (1) US12528856B2 (https=)
EP (1) EP4021582A1 (https=)
JP (1) JP2022545167A (https=)
KR (1) KR20220052919A (https=)
CN (1) CN114341193A (https=)
AU (1) AU2020336131B2 (https=)
BR (1) BR112022003553A2 (https=)
CA (1) CA3145614A1 (https=)
IL (1) IL290960A (https=)
MX (1) MX2022002297A (https=)
WO (1) WO2021041806A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023027561A1 (ko) 2021-08-27 2023-03-02 세라노틱스(주) B7-h3 및 tgfβ에 특이적으로 결합하는 이중 특이적 분자 및 이의 용도

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021312871A1 (en) 2020-07-21 2023-02-09 Allogene Therapeutics, Inc. Chimeric antigen receptors with enhanced signaling and activities and uses thereof
JP2024515181A (ja) * 2021-04-19 2024-04-05 ナンジン レジェンド バイオテック カンパニー，リミテッド キメラサイトカイン受容体及びその細胞療法における使用
CN115873802A (zh) * 2021-09-29 2023-03-31 亘喜生物科技（上海）有限公司 嵌合抗原受体免疫细胞及其制法和应用
EP4408873A1 (en) * 2021-09-29 2024-08-07 Vita Therapeutics, Inc. Methods and compositions for treating cancer with engineered cells
AU2022371471A1 (en) * 2021-10-20 2024-05-02 Fate Therapeutics, Inc. Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors
GB202117298D0 (en) * 2021-11-30 2022-01-12 Quell Therapeutics Ltd Signalling protein
CN118922196A (zh) * 2022-02-18 2024-11-08 加利福尼亚大学董事会 嵌合细胞因子受体促进原代人nk细胞扩增和功能
EP4499680A1 (en) 2022-03-29 2025-02-05 Allogene Therapeutics, Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
GB202301421D0 (en) * 2023-02-01 2023-03-15 Univ Oslo Hf Switch receptor for use in adoptive cell therapy
CN116284449B (zh) * 2023-02-27 2024-11-19 深圳市先康达生命科学有限公司 增强型TGF-βR嵌合受体及其应用
CN121240874A (zh) * 2023-06-06 2025-12-30 豪夫迈·罗氏有限公司 开关受体
CN121532650A (zh) 2023-06-20 2026-02-13 艾洛基治疗公司 工程化的细胞的检测方法
AU2024372734A1 (en) 2023-10-30 2026-04-16 Allogene Therapeutics, Inc. Engineered cells

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL114825A0 (en) 1994-08-04 1995-12-08 Regeneron Pharma Rtk/cytokine receptor chimeras
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
AU3668897A (en) 1996-07-17 1998-02-09 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
JP3499528B2 (ja) 1997-11-26 2004-02-23 中外製薬株式会社 シグナルシーケンストラップ法
WO2007075899A2 (en) 2005-12-21 2007-07-05 Maxygen, Inc. Dual agonist compounds and uses thereof
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
CA2738031C (en) 2008-09-22 2022-11-29 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
WO2011069004A1 (en) 2009-12-04 2011-06-09 Quest Diagnostics Investments Incorporated Mpl mutations in jak2 v617f negative patients with myeloproliferative disease
CA2832569A1 (en) 2011-04-08 2012-10-11 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
US10584158B2 (en) * 2013-04-17 2020-03-10 Baylor College Of Medicine Immunosuppressive TGF-β signal converter
ES2791598T3 (es) 2013-06-05 2020-11-05 Bellicum Pharmaceuticals Inc Métodos para inducir apoptosis parcial utilizando polipéptidos de caspasa
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
BR112017007003A2 (pt) 2014-10-07 2017-12-19 Cellectis método para modulação de atividade de células imunes induzidas por car
MA41538A (fr) * 2014-10-17 2017-12-26 Baylor College Medicine Cellules immunitaires bipartites et tripartites de signalisation
CN118271463A (zh) 2014-12-05 2024-07-02 纪念斯隆-凯特琳癌症中心 靶向g-蛋白偶联受体的嵌合抗原受体及其用途
HK1245827B (en) 2014-12-15 2020-06-19 Board Of Regents Of The University Of Texas System Methods for controlled activation or elimination of therapeutic cells
BR112017013981A2 (pt) 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
WO2016127257A1 (en) 2015-02-12 2016-08-18 University Health Network Chimeric antigen receptors
US10294304B2 (en) 2015-04-13 2019-05-21 Pfizer Inc. Chimeric antigen receptors targeting B-cell maturation antigen
TWI703159B (zh) 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
US20180318303A1 (en) 2015-04-15 2018-11-08 Promedior, Inc. Methods for treating myeloproliferative disorders
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201518816D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Receptor
PL3368571T3 (pl) * 2015-10-30 2023-05-02 The Regents Of The University Of California Polipeptydy odpowiadające na transformujący czynnik wzrostu beta i sposoby ich zastosowania
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
CN106399255B (zh) 2016-04-13 2019-10-18 阿思科力(苏州)生物科技有限公司 Pd-1 car-t细胞及其制备方法和应用
KR20230167769A (ko) 2016-08-26 2023-12-11 베이롤 칼리지 오브 메드신 세포 치료요법을 위한 항상성 활성 사이토킨 수용체
MA46862A (fr) 2016-11-17 2019-09-25 Bluebird Bio Inc Convertisseur de signaux tgf béta
US20190358263A1 (en) 2016-12-07 2019-11-28 Oslo Universitetssykehus Hf Compositions and Methods for Cell Therapy
GB201702617D0 (en) 2017-02-17 2017-04-05 Autolus Ltd Receptor
KR102879522B1 (ko) 2017-03-03 2025-11-04 엑수마 바이오테크, 코포레이션 림프구를 형질도입 및 팽창시키고 이들의 활성을 조절하기 위한 방법 및 조성물
EP3735460A4 (en) * 2017-09-18 2021-08-11 Exuma Biotech Corp. METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY OF THE LATTER
BR112020007542A2 (pt) * 2017-10-18 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados
GB201719557D0 (en) 2017-11-24 2018-01-10 Autolus Ltd Polypeptide
US11738047B2 (en) 2017-12-12 2023-08-29 The Trustees Of The University Of Pennsylvania Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
CN111819192A (zh) 2018-03-02 2020-10-23 艾洛基治疗公司 可诱导的嵌合细胞激素受体
EP3802578A4 (en) 2018-06-01 2022-03-23 Washington University SUPPRESSION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR CELL THERAPY
CA3102641A1 (en) 2018-06-22 2019-12-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
GB201814203D0 (en) 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
AU2020232216B2 (en) * 2019-03-01 2025-09-25 Allogene Therapeutics, Inc. Chimeric cytokine receptors bearing a PD-1 ectodomain
PE20211902A1 (es) 2019-03-01 2021-09-27 Allogene Therapeutics Inc Receptores de citocinas quimericos constitutivamente activos

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023027561A1 (ko) 2021-08-27 2023-03-02 세라노틱스(주) B7-h3 및 tgfβ에 특이적으로 결합하는 이중 특이적 분자 및 이의 용도

Also Published As

Publication number Publication date
MX2022002297A (es) 2022-03-25
AU2020336131B2 (en) 2025-09-11
BR112022003553A2 (pt) 2022-05-24
JP2022545167A (ja) 2022-10-26
WO2021041806A1 (en) 2021-03-04
EP4021582A1 (en) 2022-07-06
US20210061881A1 (en) 2021-03-04
CN114341193A (zh) 2022-04-12
US12528856B2 (en) 2026-01-20
CA3145614A1 (en) 2021-03-04
AU2020336131A1 (en) 2022-02-24
IL290960A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
KR102942957B1 (ko) Pd-1 엑토도메인을 보유하는 키메라 사이토카인 수용체
KR20220052919A (ko) Tgf 베타 결합 도메인을 포함하는 키메라 사이토카인 수용체
JP7793667B2 (ja) 誘導性キメラサイトカイン受容体
TWI894211B (zh) 具有增強活性之bcma car-t細胞
JP7667086B2 (ja) 構成的に活性なキメラサイトカイン受容体
KR20210013691A (ko) 수정된 링커 도메인을 갖는 키메라 항원 수용체 및 그 용도
RU2842294C1 (ru) Химерные цитокиновые рецепторы, содержащие домены, связывающие tgf-бета
RU2824672C2 (ru) Конститутивно активные химерные цитокиновые рецепторы
RU2826155C2 (ru) Индуцибельные химерные цитокиновые рецепторы
HK40084006A (zh) 活性增强的bcma car-t细胞
Kuo Meditope-Enabled Chimeric Antigen Receptor Confers New Functionality to T Cells
KR20240035506A (ko) 키메라 항원 수용체, 상기 수용체를 발현하는 세포, 상기 세포를 포함하는 의약 조성물, 상기 세포의 제조 방법, 및 상기 키메라 항원 수용체를 코딩하는 염기서열을 포함하는 폴리뉴클레오티드 또는 벡터

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000